In a previous blog post, we discussed certain high-level considerations for first-quarter 2020 earnings releases and guidance in the context of the macroeconomic uncertainty brought about by the novel coronavirus (COVID-19) pandemic.  We indicated our expectation that a significant number of registrants would elect to withdraw guidance in light of this uncertainty.

To get a more comprehensive view of how registrants have approached financial guidance, we analyzed disclosures in earnings releases by off-calendar year-end companies furnished with the Securities and Exchange Commission (SEC) on or after March 16, 2020.  As noted in greater detail below, a majority of companies issuing earnings releases during this period have withdrawn or suspended guidance.  This post presents the results of our analysis.

Survey Sample

At 33 earnings releases, our sample size was relatively small, but we believe this survey provides some helpful insights with respect to the approaches being taken by public companies.  Our review was limited to companies that met the following criteria:

  • Are listed on either the New York Stock Exchange or the Nasdaq Stock Market.
  • Have a prior history of providing quantitative financial guidance on a quarterly and/or yearly basis.
  • Filed an earnings release between March 16, 2020 and April 9, 2020 under Item 2.02 of Form 8-K following the conclusion of the quarter being reported.

We did not include within our survey pre-releases filed by public companies outside of their regular earnings release cycle (on the premise that the inclusion of pre-releases might skew our results given the fact that companies filing pre-releases might be more likely to be among the companies that are withdrawing or suspending guidance).

Survey Results

Of the 33 public companies fitting the criteria above, we discovered the following results:

  • 67% (22 companies) either withdrew their existing guidance (in full or in part) or suspended their practice of providing quarterly guidance.
  • 21% (seven companies) provided updated guidance, including five companies with updates indicating an expectation that the COVID-19 pandemic would have a negative effect on their results and two companies (Conagra Brands and General Mills) that made positive adjustments to their existing financial guidance.
  • 6% (two companies) provided guidance with respect to their next fiscal quarter, which was consistent with their prior practice.
  • 3% (one company, Landec Corporation) reiterated previous guidance for its current fiscal year ending May 31, 2020, but, in doing so, the company excluded “any potential impact of the COVID-19 pandemic” from its forecasts and did not provide guidance for its fourth quarter, which was inconsistent with past practice.
  • 3% (one company, H.B. Fuller Company) suspended its customary full-year guidance and instead provided guidance for the next fiscal quarter.

The companies that provided either updated guidance or new quarterly guidance generally did so with a significantly greater gap between the high and low range of their guidance compared to prior disclosures.

Notable Disclosures

As part of our review, we identified the following different approaches to financial guidance disclosure that we believe worthy of mentioning:

  • IHS Markit Ltd. made projections based on three scenarios: a recovery in the third quarter of 2020, the fourth quarter of 2020, or 2021. In each scenario, the company provided its qualitative assumptions for what such recoveries would look like for three of its four operating segments and its quantitative assumptions, including expected reductions in revenues and increased expenses, to arrive at its updated adjusted EBITDA and adjusted EPS guidance.
  • MSC Industrial Supply Co, Inc. indicated that they would provide “monthly updates on average daily sales developments following […] month-end close, as well as comments on the business trends that [management has] seen over the course of the month” for the duration of the heightened uncertainty caused by the COVID-19 pandemic.
  • Darden Restaurants, Inc. withdrew its guidance, but included in its earnings release information relating to the decline in same-restaurant sales for the first three weeks of its fourth quarter (the only available fiscal weeks at the time of the announcement) and, on its earnings call, provided fourth fiscal quarter trends by fiscal week for each of its reporting segments.

Key Takeaways for Public Companies

Our survey highlights what we have been hearing from our clients—the unfolding COVID-19 pandemic and the resulting economic turmoil make it difficult to predict what the future will look like.  As reflected in the survey results above, there will be many public companies that elect to suspend or withdraw guidance as a result of the tremendous economic uncertainty arising from COVID-19, but approaches will differ, and there will continue to be some public companies (albeit, potentially, a minority) that elect to continue to provide guidance during these uncertain times.  Ultimately, the determination of whether to continue to provide guidance will require judgment and be very fact-specific (depending on, among other things, the industry of the public company and how COVID-19 has impacted such industry).

If you have any questions regarding the upcoming earnings release process or other issues related to the impact of COVID-19 on your business, please feel free to email the authors directly or, if applicable, contact your primary Bass, Berry & Sims relationship attorney.

About the Bass, Berry & Sims Corporate & Securities Practice

Public and private companies of all sizes across a variety of industries turn to Bass, Berry & Sims for counsel on a wide range of corporate matters, including mergers, acquisitions and dispositions; capital markets transactions; executive compensation issues; corporate governance; and shareholder activism. We serve as primary corporate and securities counsel to more than 35 public companies and have counseled on 150 deals ranging in size from $20 million to more than $15 billion over the past two years. Click here to learn more about the Corporate & Securities Practice at Bass, Berry & Sims.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Kevin Douglas Kevin Douglas

Kevin Douglas has deep experience representing public companies on corporate and securities laws related matters, including companies within the healthcare industry. Kevin’s public company practice focuses on corporate governance matters, securities laws compliance, mergers and acquisitions, corporate finance and shareholder activism. His representative…

Kevin Douglas has deep experience representing public companies on corporate and securities laws related matters, including companies within the healthcare industry. Kevin’s public company practice focuses on corporate governance matters, securities laws compliance, mergers and acquisitions, corporate finance and shareholder activism. His representative experience has ranged from providing SEC disclosure advice to the audit committee of a Fortune 100 company to representing an NYSE-listed company in connection with its $4.3 billion acquisition by another public company to representing another NYSE-listed company in connection with its issuance of $2.2 billion in senior notes. Kevin has also represented private companies in a wide variety of mergers and acquisition, corporate finance, and other corporate law matters.

Photo of Tatjana Paterno Tatjana Paterno

Tatjana Paterno counsels private equity funds and their portfolio companies, strategic acquirers and multinational publicly traded corporations in the structuring, negotiation and consummation of acquisition transactions. To date, Tatjana has closed more than $22 billion in M&A transactions and more than $25 billion…

Tatjana Paterno counsels private equity funds and their portfolio companies, strategic acquirers and multinational publicly traded corporations in the structuring, negotiation and consummation of acquisition transactions. To date, Tatjana has closed more than $22 billion in M&A transactions and more than $25 billion in overall transactions. Her practice focuses on companies within the healthcare and healthcare IT, cybersecurity, manufacturing, food and beverage, entertainment and technology industries, among others. Tatjana frequently advises management, boards and special committees on corporate governance and public company disclosure matters.